Not Yet Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT04657965

LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Clinical Trial for the Safety and Efficacy of Sequential of LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Sponsor: Yake Biotechnology Ltd.

Conditions Hematological Malignancies Infectious Diseases

Interventions LMP1 CAR T-cells

Updated 3 times since 2021 Last updated: Dec 5, 2020 Started: Jan 15, 2021 Primary completion: Jan 15, 2024 Completion: Jan 15, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Hematological Malignancies and Infectious Diseases and is currently actively recruiting participants. Yake Biotechnology Ltd. leads this study, which shows 3 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yake Biotechnology Ltd.
Zhejiang University

Data source: Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China